HER2-targeted therapies have been used previously, including trastuzumab with chemotherapy against HER-2 positive metastatic osteosarcomas, and implementing HER-2-specific CAR-T for progressive glioblastoma [62,63]. The gene discussed is ERBB2; the disease is glioblastoma.